171178-21-5

Basic information

• Product Name: 6-CHLORO-3-NITROPYRIDINE-2-CARBOXAMIDE
• Synonyms: 6-CHLORO-3-NITROPYRIDINE-2-CARBOXAMIDE;2-CARBOXAMIDE-6-CHLORO-3-NITROPYRIDINE;6-chloro-3-nitro-2-PyridinecarboxaMide;6-Chloro-3-nitro-pyridine-2-carboxylic acid amide
• CAS NO: 171178-21-5
• Molecular Formula: C₆H₄ClN₃O₃
• Molecular Weight: 201.57
• Mol File: 171178-21-5.mol

Chemical Properties

• Boiling Point: 323.607°C at 760 mmHg
• Flash Point: 149.512°C
• Appearance: /
• Density: 1.611g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.633
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 13.58±0.50(Predicted)
• CAS DataBase Reference: 6-CHLORO-3-NITROPYRIDINE-2-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-3-NITROPYRIDINE-2-CARBOXAMIDE(171178-21-5)
• EPA Substance Registry System: 6-CHLORO-3-NITROPYRIDINE-2-CARBOXAMIDE(171178-21-5)

Safety Data

• Hazardous Substances Data: 171178-21-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-3-nitropyridine-2-carboxamide is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with diverse biological activities. Its presence in the synthesis process aids in the creation of compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 6-Chloro-3-nitropyridine-2-carboxamide is utilized as an intermediate in the synthesis of agrochemicals, contributing to the development of new compounds for pest control and crop protection. Its role in this industry is crucial for enhancing agricultural productivity and ensuring crop safety.
Used as a Research Tool:
6-Chloro-3-nitropyridine-2-carboxamide is used as a research tool in the study of pyridine derivatives and their biological properties. Its application in research facilitates a deeper understanding of the structure-activity relationships of pyridine-based compounds, which can lead to the discovery of novel therapeutic agents and other useful chemical entities.

InChI:InChI=1/C6H4ClN3O3/c7-4-2-1-3(10(12)13)5(9-4)6(8)11/h1-2H,(H2,8,11)

Upstream product

• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 93683-65-9 6-chloro-3-nitropicolinonitrile 

Downstream Products

• 1400633-18-2 6-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-3-nitropyridine-2-carboxamide 
• 1400633-20-6 2,4-dichloro-6-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrido[3,2-d]pyrimidine 
• 1400633-19-3 3-amino-6-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyridine-2-carboxamide 
• 1400633-11-5 6-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-2-methoxy-N-[4-(4-methylpiperazin-1-yl)phenyl]pyrido[3,2-d]pyrimidin-4-amine 
• 1400633-10-4 2-chloro-6-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-N-[4-(4-methylpiperazin-1-yl)phenyl]pyrido[3,2-d]pyrimidin-4-amine 
• 171178-33-9 6-chloropyrido[3,2-d]pyrimidin-4(1H)-one 
• 37538-67-3 pyrido[3,2-d]-pyrimidin-4(3H)-one 
• 175358-02-8 4,6-dichloropyrido<3,2-d>pyrimidine 
• 171178-33-9 6-chloropyrido<3,2-d>pyrimidin-4(3H)-one 
• 51674-77-2 4-chloropyrido<3,2-d>pyrimidine 
• 267243-55-0 6-amino-4-[N-(3-chloro-4-fluorophenyl)amino]-7-[4-(4-morpholinyl)butyl]pyrido[3,2-d]pyrimidine 
• 267243-53-8 6-amino-4-[N-(3-chloro-4-fluorophenyl)amino]-7-[(1E)-4-(4-morpholinyl)-1-butenyl]pyrido[3,2-d]pyrimidine 

Relevant articles and documents

NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

2-METHYL-AZA-QUINAZOLINES

The present invention covers 2-methyl-aza-quinazoline compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients

QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES

The present invention encompasses compounds of general formula (1), wherein the groups R1 to R4, X1, X2, X3, X4, X5, Q, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor

Following the discovery of the very high inhibitory ability of the 4-[(3-bromophenyl)amino]-quinazolines against the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) (e.g., 3, IC50 0.029 nM), four series of related pyrido[d]pyrimidines bearing electron-donating groups at the 6- or 7-positions have been synthesized and evaluated. The compounds were prepared by nucleophilic substitution of the corresponding 6- and 7-fluoro analogues. While members of all series showed potent inhibitory activity against isolated EGFR, there were important differences between the different isomeric pyrido[d]pyrimidines and the parent quinazolines. Overall, the [3,4-d] and [4,3-d] series were the most potent, followed by the [3,2-d] compounds, with the [2,3-d] analogues being least active. Whereas in the parent quinazoline series the addition of steric bulk to a 6- or 7-NH2 substituent (i.e., NHMe and NMe2 groups) dramatically decreased potency, no such trend was discernable in the [3,2-d] series. Furthermore, in the 7-substituted pyrido[4,3-d]- and 6-substituted pyrido[3,4-d]pyrimidine series, and to a limited extent in the 7-substituted pyrido[2,3-d] series, such substitution increased potency dramatically, to the extent that the 7-(methylamino)pyrido[4,3-d]pyrimidine (5f) (IC50 0.13 nM) and 6-(methylamino)pyrido[3,4-d]pyrimidine (7f) (IC50 0.008 nM) constitute important new leads. Selected compounds were evaluated for their ability to inhibit EGFR autophosphorylation in A431 cells, and a positive quantitative correlation was found between this activity and inhibitory activity against the isolated enzyme.